Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry

Cellular Physiology and Biochemistry

Volumn 20, Issue 5, 2007, Pages 579-590

  Leong, Sharon ^a   Christopherson, Richard I ^b   Baxter, Robert C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Apoptosis; Breast cancer; Chemotherapeutic drugs; Mass spectrometry; Protein chips; Proteomics; SELDI; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CALCYCLIN; CASPASE 3; ETOPOSIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 34548334619     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107541     Document Type: Article

References (44)

1. Jin Z, El-Deiry WS: Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-163.
2. Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM: Caspase activation inhibits proteasome function during apoptosis. Mol Cell 2004;14:81-93.
3. Suliman A, Lam A, Datta R, Srivastava RK: Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001;20:2122-2133.
4. Fulda S, Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-4811.
5. Galluzzi L, Larochette N, Zamzami N, Kroemer G: Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006;25:4812-4830.
6. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X: Bid, a bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-490.
7. Wang S, El-Deiry WS: TRAIL and apoptosis induction by tnf-family death receptors. Oncogene 2003;22:8628-8633.
8. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162.
9. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.
10. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK: Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003;63:5390-5400.
11. Ozoren N, El-Deiry WS: Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003;13:135-147.
12. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59:734-741.
13. Hutchens TW, Yip TT: New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993;7:576-580.
14. Issaq HJ, Veenstra TD, Conrads TP, Felschow D: The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587-592.
15. Tang N, Tornatore P, Weinberger SR: Current developments in SELDI affinity technology. Mass Spectrom Rev 2004;23:34-44.
16. Gatlin CL, Kleemann GR, Hays LG, Link AJ, Yates JR, 3rd: Protein identification at the low femtomole level from silver-stained gels using a new fritless electrospray interface for liquid chromatography-microspray and nanospray mass spectrometry. Anal Biochem 1998;263:93-101.
17. Schagger H, von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 1987;166:368-379.
18. Almond JB, Cohen GM: The proteasome: A novel target for cancer chemotherapy. Leukemia 2002;16:433-443.
19. Peng J, Gygi SP: Proteomics: The move to mixtures. J Mass Spectrom 2001;36:1083-1091.
20. Hancock WS, Wu SL, Shieh P: The challenges of developing a sound proteomics strategy. Proteomics 2002;2:352-359.
21. Vogl T, Roth J, Sorg C, Hillenkamp F, Strupat K: Calcium-induced noncovalently linked tetramers of MRP8 and MRP14 detected by ultraviolet matrix-assisted laser desorption/ionization mass spectrometry. J Am Soc Mass Spectrom 1999;10:1124-1130.
22. Konig S, Zeller M, Peter-Katalinic J, Roth J, Sorg C, Vogl T: Use of nonspecific cleavage products for protein sequence analysis as shown on calcyclin isolated from human granulocytes. J Am Soc Mass Spectrom 2001;12:1180-1185.
23. Donato R: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003;60:540-551.
24. Heizmann CW, Fritz G, Schafer BW: S100 proteins: Structure, functions and pathology. Front Biosci 2002;7:d1356-1368.
25. Harrison CA, Raftery MJ, Walsh J, Alewood P, Iismaa SE, Thliveris S, Geczy CL: Oxidation regulates the inflammatory properties of the murine S100 protein S100A8. J Biol Chem 1999;274:8561-8569.
26. Emberley ED, Murphy LC, Watson PH: S100 proteins and their influence on prosurvival pathways in cancer. Biochem Cell Biol 2004;82:508-515.
27. Boom A, Pochet R, Authelet M, Pradier L, Borghgraef P, Van Leuven F, Heizmann CW, Brion JP: Astrocytic calcium/zinc binding protein S100A6 over expression in Alzheimer's disease and in ps1/app transgenic mice models. Biochim Biophys Acta 2004;1742:161-168.
28. Ilg EC, Schafer BW, Heizmann CW: Expression pattern of S100 calcium-binding proteins in human tumors. Int J Cancer 1996;68:325-332.
29. Pedrocchi M, Schafer BW, Mueller H, Eppenberger U, Heizmann CW: Expression of Ca(2+)-binding proteins of the S100 family in malignant human breast-cancer cell lines and biopsy samples. Int J Cancer 1994;57:684-690.
30. Weterman MA, Stoopen GM, van Muijen GN, Kuznicki J, Ruiter DJ, Bloemers HP: Expression of calcyclin in human melanoma cell lines correlates with metastatic behavior in nude mice. Cancer Res 1992;52:1291-1296.
31. Svasti J, Srisomsap C, Subhasitanont P, Keeratichamroen S, Chokchaichamnankit D, Ngiwsara L, Chimnoi N, Pisutjaroenpong S, Techasakul S, Chen ST: Proteomic profiling of cholangiocarcinoma cell line treated with pomiferin from derris malaccensis. Proteomics 2005;5:4504-4509.
32. Choufani G, Mahillon V, Decaestecker C, Lequeux T, Danguy A, Salmon I, Gabius HJ, Hassid S, Kiss R: Determination of the levels of expression of sarcolectin and calcyclin and of the percentages of apoptotic but not proliferating cells to enable distinction between recurrent and nonrecurrent cholesteatomas. Laryngoscope 1999;109:1825-1831.
33. Philchenkov A: Caspases: Potential targets for regulating cell death. J Cell Mol Med 2004;8:432-444.
34. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD: Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004;23:2009-2015.
35. Canu N, Barbato C, Ciotti MT, Serafino A, Dus L, Calissano P: Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J Neurosci 2000;20:589-599.
36. Chen ZJ: Ubiquitin signalling in the nf-kappab pathway. Nat Cell Biol 2005;7:758-765.
37. Harris SL, Levine AJ: The p53 pathway: Positive and negative feedback loops. Oncogene 2005;24:2899-2908.
38. Wing SS: Deubiquitinating enzymes - the importance of driving in reverse along the ubiquitin-proteasome pathway. Int J Biochem Cell Biol 2003;35:590-605.
39. Li B, Dou QP: Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000;97:3850-3855.
40. Bernardi P, Petronilli V, Di Lisa F, Forte M: A mitochondrial perspective on cell death. Trends Biochem Sci 2001;26:112-117.
41. Kaulsay KK, Zhu T, Bennett W, Lee KO, Lobie PE: The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 2001;142:767-777.
42. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ: The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003;102:303-310.
43. Nowotny M, Spiechowicz M, Jastrzebska B, Filipek A, Kitagawa K, Kuznicki J: Calcium-regulated interaction of Sgt1 with S100A6 (calcyclin) and other S100 proteins. J Biol Chem 2003;278:26923-26928.
44. Thiede B, Kretschmer A, Rudel T: Quantitative proteome analysis of CD95 (Fas/Apo-1)-induced apoptosis by stable isotope labeling with amino acids in cell culture, 2-DE and MALDI-MS. Proteomics 2006;6:614-622.